In conclusion, despite long-term dose escalation of STX140 in A2780 ovarian cancer cells resulting in a sub-line which expresses high levels of wild-type BCRP, STX140, in contrast to MXR, is highly efficacious in vivo in both wild-type and BCRP-expressing tumour xenografts. The gene discussed is ABCG2; the disease is ovarian cancer.